Medical/Pharmaceuticals
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B
-- Estimated 1.59 million chronic hepatitis B (CHB) patients in the U.S. -- Interim results of the Phase IIb trial conducted on CHB patients in China showed that in patients with the baseline hepatitis B surface antigen (HBsAg) level ≤ 500 IU/mL, approximately 19% (3/16) of patients in the treatm...
2022-01-17 18:12
5199
HTPE Leads JYSSBIO to Close Series B+ Funding
HANGZHOU, China, Jan. 17, 2022 /PRNewswire/ -- Huatai International Private Equity Fund ("HTPE"), the Greater China focused private equity investment platform under Huatai Securities, is pleased to announce that it led the Series B+ financing ofZhejiang JYSS Bio-Engineering Co., Ltd. ("JYSSBIO" ...
2022-01-17 17:58
5123
Frost & Sullivan and TERI's Sustainability 4.0 Awards 2021 Honor Companies Embedding Sustainability with Economic Value Creation
At the 12th edition, 23 awards were presented to companies for their exemplary performance in sustainability MUMBAI, India, Jan. 17, 2022 /PRNewswire/ -- The 12th edition of Frost & Sullivan and The Energy and Resources Institute (TERI)'s Sustainability 4.0 Awards took place virtually on Jan. 12...
2022-01-17 17:30
5999
The Philippines Has Approved ReCOV For Phase II/III Cinical Trial
* Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clinical Trial * ReCOV induced high levels of neutralizing antibodies against SARS-CoV-2 and Variants of Concern such as Omicron and Delta * Rhecogen , a subsidiary focused on mRNA vaccines of th...
2022-01-17 16:57
3895
Leading E-commerce Logistics and Fulfillment Brand NextSmartShip Partners with B2B Medical E-commerce Giant LyncMed
SHENZHEN, China, Jan. 17, 2022 /PRNewswire/ -- NextSmartShip
2022-01-17 15:00
2241
MicroPort CRM Receives Approval in Japan for Alizea Bluetooth Pacemaker
CLAMART, France, Jan. 17, 2022 /PRNewswire/ -- MicroPort CRM, a pioneering company in the field of Cardiac Rhythm Management, headquartered inFrance, recently received PMDA Japanese regulation agency approval for its latest range of implantable pacemakers, Alizea. The devices are equipped with Bl...
2022-01-17 12:18
4254
Xinhua Silk Road: BGI Genomics' star COVID-testing mobile lab product exhibited at China Pavilion of Expo 2020 Dubai
BEIJING, Jan. 17, 2022 /PRNewswire/ -- Models of BGI Genomics' Huo-Yan Air Laboratory, a star nucleic acid-testing mobile lab product of the Chinese giant, were displayed at the China Pavilion of Expo 2020 Dubai duringJanuary 11-13. Compared with regular COVID-testing labs, Huo-Yan Air Labs are ...
2022-01-17 10:22
2405
CStone announces the clinical data from registrational study of Sugemalimab in stage III non-small cell lung cancer published in The Lancet Oncology
SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the registrational clinical...
2022-01-15 08:35
6934
CStone announces the registrational clinical study results of sugemalimab in stage IV non-small cell lung cancer published in The Lancet Oncology
SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that results of the GEMSTONE-302...
2022-01-15 08:31
6382
French Consul General in Guangzhou led a delegation to visit Biosyngen in China-Singapore Guangzhou Knowledge City
GUANGZHOU, ChinaJan. 15, 2022 /PRNewswire/ -- On the afternoon of January 14th, Mr. Sylvain FOURRIERE, Consul General ofFrance in Guangzhou, and officers from consulates general of 9 countries includingBritain, Canada and Switzerland visited China-Singapore Guangzhou Knowledge City andSingapore -...
2022-01-15 08:00
7072
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
Results from ongoing testing and monitoring of COVID-19 variants shows the rapid microfluidic test detects Omicron at a comparable sensitivity to other variants LONDON, Jan. 14, 2022 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced tha...
2022-01-14 19:18
3760
Crunchfish Gesture Interaction introduction - Deeply intuitive gestures
STOCKHOLM, Jan. 14, 2022 /PRNewswire/ -- Crunchfish develops AI technology for gesture interaction with exceptional performance, optimized for augmented and virtual reality (AR/VR), automotive and the next generation digital interfaces. An introduction to gesture Interaction was the topic of the ...
2022-01-14 19:17
3361
Everest Medicines Enters into a Global Licensing Agreement to Develop and Commercialize Singapore's Experimental Drug Development Centre's 3CL Protease Inhibitors as Potentially Best-in-Class COVID-19 Oral Antiviral Treatments Worldwide
SHANGHAI, Jan. 14, 2022 /PRNewswire/ -- Everest Medicines
2022-01-14 08:00
6440
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne
HANGZHOU and SHAOXING, China, Jan. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC40 for moderate to severe acne. ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme whic...
2022-01-13 17:30
4963
Apex Medical Rebrands to Wellell, redefining core values
NEW TAIPEI CITY, Taiwan, Jan. 13, 2022 /PRNewswire/ -- Apex Medical has placed utmost importance on the value of human life, while providing agile services and high-quality medical devices since 1990. The rebranding in 2022 affirms the determination to establish a global foothold and further evol...
2022-01-13 16:00
3935
Accuredit Therapeutics and N1 Life Form a Joint Venture Named 'Napoltec', Dedicated to the Development of Therapeutic Drug Delivery Systems and Pressing Ahead Clinical Translation
SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Accuredit Therapeutics (Suzhou) Co., Ltd. (hereinafter referred to as Accuredit), an emerging company based on new generations of safe and highly targeted gene editing therapies, and N1 Life, a biotech company focused on developing cutting-edge drug de...
2022-01-13 13:33
4428
NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression
SINGAPORE, Jan. 13, 2022 /PRNewswire/ -- Moleac is pleased to announce the release of the ATHENE study results, published in the Journal of the American Medical Director Association (JAMDA)1. Alzheimer's Disease (AD) and other dementias cause a heavy economic and public healthcare burden worldw...
2022-01-13 12:32
4672
Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046
* Interim analysis expected in the second quarter of 2022 SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical study of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) (KN026-203) has su...
2022-01-13 10:46
3995
CStone announces phase 2 GEMSTONE-201 trial met primary endpoint of objective response rate (ORR) in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL)
* Sugemalimab has the potential to become the world's first immunotherapy to be approved for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) * The National Medical Products Administration (NMPA) of China has granted the Breakthrough Therapy Designati...
2022-01-13 08:05
7862
Seegene Unveils Blueprint for the Future of Molecular Diagnostics, Including Open Development Platform at the 40th Annual J.P. Morgan Healthcare Conference
SEOUL, South Korea, Jan. 13, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics (MDx) company, today, unveiled its blueprint for the future during a presentation at the 40th annual J.P. Morgan Healthcare virtual Conference. Dr.Jong-Yoon Chun, CEO of Seegene...
2022-01-13 04:00
3874
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 295 media titles]
2026-09-18 16:29CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 289 media titles]
2026-09-22 18:37
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 276 media titles]
2026-09-23 09:00
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 275 media titles]
2026-09-21 08:00Most Read
COSRX Brings Its 5 Peptide Lip Collection to Ulta Beauty Stores Offline
2026-09-18 22:00
11182
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
2026-09-17 13:09
10316
Ohmyhome Limited Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
2026-09-17 20:00
8545
American Savings Bank Jumps More Than 6% in Trading Debut: NYSE Content Update
2026-09-17 21:21
8101
Sea, Gardens, Lawns and Hearths: Life Abroad Across Noah's N+ Club Network
2026-09-18 23:04
7848